OOIR: Observatory of International Research

Papers

(The H4-Index of Blood Reviews is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Transplant-acquired allergy in HCT-recipients: Reference for clinical management	100
Pitfalls in laboratory monitoring of treatment in people with Haemophilia	71
Editorial Board	69
Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond	68
Thalassaemia in China	65
Advances in the critical care management for patients with hematological malignancies	65
Artificial intelligence in sickle disease	62
Radiation and leukaemia: Which leukaemias and what doses?	62
Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach	58
Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?	56
Not all LGL leukemias are created equal	54
Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond	48
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma	47
Targeting the neonatal Fc receptor (FcRn) in hematologic conditions with a focus on warm autoimmune hemolytic anemia	47
Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk	46
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need	45
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies	42
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT	42
Artificial intelligence in myeloid malignancies: Clinical applications of machine learning in myelodysplastic syndromes and acute myeloid Leukemia	41
Breaking down frailty: Assessing vulnerability in acute myeloid leukemia	40
Adenovirus infection in adult allogeneic hematopoietic stem cell transplant recipients: Systematic review and meta-analysis	40
Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103]	39
Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs	38
Ph-chromosome-negative myeloproliferative neoplasms: clonal dynamics are the name of the game	34
Chasing leukemia differentiation through induction therapy, relapse and transplantation	34

Harnessing multi-source data for individualized care in Hodgkin Lymphoma	31
CHIPing away the progression potential of CHIP: A new reality in the making	30
Gut microbiome composition and dysbiosis in immune thrombocytopenia: A review of literature	30
The acute pain crisis in sickle cell disease: What can be done to improve outcomes?	29
Clostridioides difficile infection in non-transplanted adults with haematological malignancy: Systematic review and meta-analysis on behalf of European Conference on Infections in Leukemia (ECIL) and	29
Preservation of fertility in female patients with hematologic diseases	29